Definitive Healthcare Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 3, 2022, by Definitive Healthcare Corp. (DH), a Delaware corporation. The filing primarily reports the appointment of a new President and references the announcement of financial results for the third quarter ended September 30, 2022.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the Q3 2022 financial results but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the text of this 8-K. Investors must refer to the incorporated press release for these figures.
Material Changes and Executive Appointment
The Board of Directors appointed Jonathan Maack as President, effective November 3, 2022. Mr. Maack previously served as Chief Strategy and Corporate Development Officer at athenahealth and held senior leadership roles at OptumInsight and The Advisory Board Company.
Compensation and Employment Terms
- Base Salary: $400,000 annually.
- Annual Bonus: Target of 70% of base salary. For 2022, a guaranteed pro-rated amount is provided; future years are discretionary based on revenue targets.
- Equity Grant: Initial grant of 546,303 Restricted Stock Units (RSUs). Vesting schedule: 25% on November 3, 2023, followed by 6.25% quarterly for three years.
- Future Equity: Eligible for a 2024 annual equity award with a recommended target grant value of at least $2 million.
- Relocation: One-time lump-sum payment of $330,000, subject to repayment if employment terminates within 24 months.
- Benefits: 100% reimbursement of health insurance premiums.
Severance and Change of Control Provisions
Termination without Cause/Good Reason:
- 12 months of base salary continuation.
- Payment of earned prior bonuses plus a lump sum for the subsequent 12-month period (greater of target or 2-year average).
- Acceleration of time-based equity vesting for the 12-month post-termination period.
- 12 months of COBRA coverage.
Change of Control Termination:
- 18 months of base salary continuation.
- 1.5x multiplier on the bonus calculation (target or 2-year average).
- Full acceleration of all equity awards.
- 18 months of COBRA coverage.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q3 2022 revenue, net income, and cash flow figures not detailed in this summary.
- Verify the total number of outstanding shares to assess the dilution impact of the 546,303 RSU grant.
- Confirm the pro-rated bonus calculation for Mr. Maack's 2022 tenure.
- Monitor the vesting schedule of the Initial RSU Grant and the terms of the proposed 2024 Award.